Ticker

NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system (“CNS”) diseases with high unmet medical needs, today announced that it has received confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with…

CENTENNIAL, Colo., Sept. 01, 2026 (GLOBE NEWSWIRE) -- PVG Asset Management Corporation (“PVG”), together with the other participants named below, has filed a definitive proxy statement on Schedule 14A (the “Definitive Proxy Statement”) and accompanying GOLD Universal Proxy Card with the U.S. Securities and Exchange Commission (the “SEC”) in connection with its solicitation of proxies from stockholders of Anavex Life…

Anavex Life Sciences (AVXL) has experienced a significant stock increase following its Q3 update, highlighting regulatory advancements for its lead drug, blarca

Clinical Development Strategy for Alzheimer's Disease Remains the Focus as Anavex Advances Regulatory Progress Across All Three Programs Anavex Submits Completed Alzheimer's Disease Clinical Study Data and Rett Syndrome Formal Meeting Request to FDA, with an IND Submission for Fragile X Syndrome Planned for September NEW YORK, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”)…

Launches  VoteAnavex.com to Provide Additional Information on Anavex's Director Nominees and How to Vote at the Annual Meeting of Stockholders